

Linking DNT In Vitro Battery Endpoints to Adverse Outcome Pathways using Omics Approaches



Timothy J Shafer, PhD
Center for Computational Toxicology and Exposure
Biomolecular and Computational Toxicology Division
Rapid Assay Development Branch
Shafer.tim@epa.gov



Disclosure:

This work has been funded by the US. Environmental Protection Agency. I have no conflicts to declare.

This is a scientific presentation only. Some or all of the data presented in this presentation may be preliminary and subject to change.

This presentation does not represent EPA policy and mention of products or tradenames does not constitute a recommendation for use or endorsement. **Do not cite or quote this presentation.**

Alignment of DNT IVB assays with AOPs



ELSEVIER

Contents lists available at ScienceDirect

Neurotoxicology

journal homepage: www.elsevier.com/locate/neuro

Archives of Toxicology (2019) 93:2759–2772
<https://doi.org/10.1007/s00204-019-02551-1>

REGULATORY TOXICOLOGY



Development and analysis of an adverse outcome pathway network for human neurotoxicity

Nicoleta Spinu¹ · Anna Bal-Price² · Mark T. D. Cronin¹ · Steven J. Enoch¹ · Judith C. Madden¹ · Andrew P. Worth²


Received: 15 June 2019 / Accepted: 14 August 2019 / Published online: 23 August 2019
© The Author(s) 2019

Identification of neurotoxicology (NT)/developmental neurotoxicology (DNT) adverse outcome pathways and key event linkages with *in vitro* DNT screening assays

Emily M. Pitzer^{a,*}, Timothy J. Shafer^b, David W. Herr^a


^a Center for Public Health and Environmental Assessment, US Environmental Protection Agency, Research Triangle Park, NC 27711, USA

^b Center for Computational Toxicology and Exposure, US Environmental Protection Agency, Research Triangle Park, NC 27711, USA



Aschner et al., ALTEX. 2017;34(1):49-74. doi: 10.14573/altex.1604201

Aligning different data streams to the AOP concept





Linking DNT-NAMs data to AOPs



- Few endorsed AOPs exist for DNT
 - Especially if thyroid related AOPs are excluded
 - These AOPs are not necessarily driven by data from the DNT NAMs
- Is there another approach that would use data to establish linkages between data from DNT NAMs and AOPs for neurodevelopment?
 - Could this also help to establish human relevance?

Could Omics data help link data from in vitro DNT assays to AOPs?



Toxicology and Applied Pharmacology 354 (2018) 81–93



ELSEVIER

Contents lists available at ScienceDirect





Toxicology and Applied Pharmacology

journal homepage: www.elsevier.com/locate/taap




Defining toxicological tipping points in neuronal network development[☆]

Christopher L. Frank^{a,1}, Jasmine P. Brown^{a,2}, Kathleen Wallace^a, John F. Wambaugh^b, Imran Shah^b, Timothy J. Shafer^{a,*}




**Critical concentration
("tipping point")
determined = 0.046 μ M for
Cytosine Arabinoside**

The Concept of Toxicological “Tipping Points”





The “Tipping Point” is a mathematical determination of the point at which the system transitions from homeostasis to toxicity

Proof-of-Concept for collecting -omics information from the rat network formation assay




Step 1: Chemical Dose Identification with Functional Assay




Selected Treatments

Step 2: Identifying Key Molecular Events Involved in Neurodevelopment



Transcriptomics

+



Metabolomics

3: Integrated Core Analysis

Transcriptomic level
Disease Analysis (NDD)
Molecular/Cellular
Function Categories

Metabolomic level
Disease Analysis (NDD)
Molecular/Cellular
Function Categories

Combined Analysis

Disease Analysis (NDD)
Molecular/Cellular
Function Categories

Proof-of-Concept for collecting -omics information from the rat network formation assay




Table 1. Compounds Tested


Compound Name (Abbreviation)	Proposed Target	CAS No.	DTXSID	Tipping Point ^a (μM [$\pm 95\%$ CI])	Concentrations Tested (μM)	Min Viability ^b EC ₅₀ (μM)	Solvent Used	Source
Cytosine arabinoside (CA)	DNA synthesis inhibitor	147-94-4	DTXSID3022877	0.046 [0.04–0.06]	1	0.84	DMSO	Sigma-Aldrich
5-Fluorouracil (5FU)	DNA synthesis inhibitor	51-21-8	DTXSID2020634	0.14 [0.10–0.17]	1	2.28	DMSO	Sigma-Aldrich
Domoic acid (DA)	Glutamate Receptor Agonist	14277-97-5	DTXSID20274180	0.21 [0.9–0.25]	0.3	NA	Water	Sigma-Aldrich
Cypermethrin (CM)	Voltage-gated Sodium Channel Modulator	52315-07-8	DTXSID1023998	0.28 [0.19–0.38]	3.10	NA	DMSO	Chem Service, Inc.
Deltamethrin (DM)	Voltage-gated Sodium Channel Modulator	52918-63-5	DTXSID8020381	0.05 [0.04–0.15]	3.10	NA	DMSO	Chem Service, Inc.
Haloperidol (HP)	Dopamine Receptor Agonist	52-86-8	DTXSID4034150	0.31 [0.15–0.49]	3	13.9	DMSO	Sigma-Aldrich

Principal Components Analysis for Differentially Expressed Genes and Metabolites indicate treatment effects

Metabolites





Genes





Categories Associated With Functional Alterations in Network Development



Cellular and Molecular Function



Disease and Disorders



Canonical Pathways Associated With Functional Alterations in Network Development



Table 3. Canonical Pathways Associated With Altered Network Formation Using Integrated Pathway Analysis

Cytosine Arabinoside (CA)	5-Fluorouracil (5FU)	Domoic Acid (DA)	Cypermethrin (CM)	Deltamethrin (DM)	Haloperidol (HP)
• CREB signaling in neurons • Axonal guidance signaling • Osteoarthritis pathway • Human embryonic stem cell pluripotency • Hepatic fibrosis/hepatic stellate cell activation	• WNT/β-catenin signaling • Axonal guidance signaling • tRNA charging • Hepatocyte Growth Factor (HGF) signaling • Nicotinamide adenine dinucleotide (NAD) signaling pathway • Hepatic fibrosis/hepatic stellate cell activation	• tRNA charging • Phenylalanine degradation IV (mammalian, via side chain) • Glycine biosynthesis III • Purine nucleotides de novo biosynthesis II • Tyrosine biosynthesis IV	• Alanine biosynthesis III • Glycine biosynthesis III • Catecholamine biosynthesis • tRNA charging • Glycine Biosynthesis III • Thio-molybdenum cofactor biosynthesis	• (S)-reticuline biosynthesis II • Tyrosine degradation I • 4-hydroxybenzoate biosynthesis • 4-hydroxyphenylpyruvate biosynthesis • tRNA charging	• Phenylalanine degradation I • Threonine degradation II • Tyrosine biosynthesis IV • Glycine biosynthesis III • tRNA charging

Upstream Regulators Associated with Functional Alterations in Network Development




Table 4. Top Upstream Regulators Associated with Chemical Exposures That Alter Network Formation

	Cytosine Arabinoside (CA)	5-Fluorouracil (5FU)	Domoic Acid (DA)	Cypermethrin (CM)	Deltamethrin (DM)	Haloperidol (HP)
Transcriptomic regulators	CREB1↑	SOX2↓	LOC102724788/ PRODH	ARX	ATXN1	CREB1
	SOX2↓	TCF7L2↓	SLC1A2	LOC102724788/ PRODH	GLS	CA9
	ZBTB17	PRMT1↓	ELAVL4	SLC1A2	HPRT1	CPT1B
	S100A8↑	PPP3CA	GLS	KLF9	ELAVL4	
Metabolomic regulators	β-estradiol	NOTCH1	Kynurenic acid	SLC23A2	K+	Afatinb GSKJ4

Predicted activation (↑) and inhibition (↓). Lack of a directional arrow indicates that activation or inhibition could not be predicted.

A Putative AOP based on NAMs and Omics Data



Next Step: Confirm with additional data



Chemical	Functional Category	CAS No.	DTXSID	Tipping Point* (μM [$\pm 95\%$ CI])	Concentrations Tested (μM) LOW/MID/HIGH	Min AC ₅₀ Endpoint*	Min AC ₅₀ Viability (μM)*
Tebuconazole	Fungicides	107534-96-3	DTXSID9032113	1.341 [0.122-4.382]	0.3, 1, 3	0.99	20.4
Flusilazole	Fungicides	85509-19-9	DTXSID3024235	0.085 [0.043-0.291]	0.03, 0.1, 0.3	1.6	13.2
Dieldrin	GABA Modulators	60-57-1	DTXSID9020453	1.035 [0.347-2.177]	0.3, 1, 3	0.7	11.6
Heptachlor Epoxide	GABA Modulators	1024-57-3	DTXSID1024126	1.737 [1.288-1.995]	0.3, 1, 3	1.5	19.5
Lindane	GABA Modulators	58-89-9	DTXSID2020686	0.799 [0.267-4.782]	0.3, 1, 3	0.5	ND
Fipronil	GABA Modulators	120068-37-3	DTXSID4034609	0.799 [0.158-3.089]	0.3, 1, 3	15.6	25.3
Cadmium	Metals	7790-78-5	DTXSID4040183	0.036 [0.036-0.043]	0.01, 0.03, 0.1	0.04	0.48
Lead Acetate	Metals	6080-56-4	DTXSID3031521	2.916 [1.828-4.382]	1, 3, 10	0.5	16.1
Tributyltin oxide	Metals	56-35-9	DTXSID9020166	0.005 [0.004-0.006]	0.001, 0.003, 0.01	0.02	0.03
Triethyltin bromide	Metals	2767-54-6	DTXSID9040712	0.022 [0.017-0.024]	0.003, 0.01, 0.03	0.07	0.06
Sodium Arsenite	Metals	7784-46-5	DTXSID5020104	0.092 [0.055-0.122]	0.03, 0.1, 0.3	1.0	1.1
Chlorpyrifos	Organophosphates	2921-88-2	DTXSID4020458	1.23 [0.072-1.828]	0.3, 1, 3	13.1	13.7
Chlorpyrifos oxon	Organophosphates	5598-15-2	DTXSID1038666	0.071 [0.039-0.133]	0.03, 0.1, 0.3	0.4	0.3
PBDE-47	Other	5436-43-1	DTXSID3030056	1.155 [0.302-2.262]	0.3, 1, 3	0.01	11.6
Permethrin	Other	52645-53-1	DTXSID8022292	0.871 [0.64-1.288]	0.3, 1, 3	5.7	9.2
Bis(2-ethylhexyl) phthalate	Other	117-81-7	DTXSID5020607	0.11 [0.055-0.224]	0.03, 0.1, 0.3	2.0	12.3
Methylchloroisothiazolinone	Other	26172-55-4	DTXSID9034286	0.436 [0.245-0.64]	0.1, 0.3, 1	2.0	4.61
Paraquat dichloride [‡]	Other	1910-42-5	DTXSID7024243	0.142 [0.102-0.205]	0.03, 0.1, 0.3	0.8	1.7

*Frank et al. (2018).

*From ToxCast; may differ from values reported in Frank et al. (2017).

‡CAS No. and DTXSID were incorrectly reported in Frank et al 2017 and 2018.

Treatments caused more metabolomic than transcriptomic changes



Differentially Expressed Genes (DEGs) and Significant Metabolites at Tested Doses

Chemical	No. DEGs			No. Metabolites		
	LOW	MID	HIGH	LOW	MID	HIGH
Tebuconazole	1	51	923	101	82	350
Flusilazole	-	-	-	133	72	49
Dieldrin	-	-	-	107	137	65
Heptachlor Epoxide	-	-	-	149	54	139
Lindane	-	-	-	557	202	86
Fipronil	96	125	208	139	75	135
Cadmium	-	-	8	114	432	62
Lead Acetate	96	221	895	148	295	392
Tributyltin oxide	-	13	103	148	157	117
Triethyltin bromide	-	-	-	585	399	244
Sodium Arsenate	-	-	9	48	81	415
Chlorpyrifos	-	1	-	65	75	48
Chlorpyrifos oxon	-	-	-	44	79	68
PBDE-47	-	-	-	41	96	125
Permethrin	-	-	32	78	285	125
Bis(2-ethylhexyl) phthalate	-	-	-	243	137	113
Methylchloroisothiazolinone	-	-	249	215	384	194
Paraquat	-	-	1	57	93	114

Many fewer DEGs observed here. Therefore, focus on compounds with concentration-dependent changes in DEGs.



Top Diseases and Functions Associated With Functional Alterations in Network Development



Tebuconazole

- Cell Death and Survival
- Neurological Disease
- Organismal Injury and Abnormalities
- Cellular Development
- Nervous System Development and Function

Lead Acetate

- Cell Morphology,
- Cellular Assembly and Organization
- Molecular Transport
- Cell-To-Cell Signaling and Interaction
- Nervous System Development and Function
- Neurological Disease
- Psychological Disorders

Tributyltin

- Amino Acid Metabolism
- Cell-To-Cell Signaling and Interaction
- Cell Death and Survival
- Cellular Growth and Proliferation
- Neurological Disease
- Nervous System Development and Function

Fipronil

- Cell Morphology
- Cell Development
- Tissue Morphology
- Neurological Disease
- Nervous System Development and Function,



Top Upstream Regulators


Cytosine Arabinoside (CA)	5-Fluorouracil (5FU)	Domoic acid (DA)	Cypermethrin (CM)	Deltamethrin (DM)	Haloperidol (HP)	Lead Acetate	Tributyltin Chloride	Fipronil	Tebuconazole
CREB1↑ SOX2↓ ZBTB17 S100A8↑	SOX2↓ TCF7L2↓ PRMT1↓ PPP3CA NOTCH1	LOC102724788/ PRODH SLC1A2 ELAVL4 GLS	ARX LOC102724788/ PRODH SLC1A2 KLF9 SLC23A2	ATXN1 GLS HPRT1 ELAVL4	CREB1 CA9 CPT1B	SOX2↓ KDM1A PPP3CA inosine↓ MYOC↓ MAPT CX3CL1 HTT APP↓	MAPT PSEN1 APP HTT BDNF↑ MKNK1↑ ATN1 FMR1↓ GRN CYP27A1	SOX2↑ BDNF CHMP2B CREB1 HTT GRN SERPINF1 CSF1	TARDBP↑ PROM1 SH3TC2↑ LMNB1 SIRT2↑ SOX2↑ NR1H3 NR1H2 CYP27A1↑

Our analysis indicates that there are a number of common upstream regulators across the active chemicals. However, there is also considerable heterogeneity in the identified upstream regulators.


Analysis could inform AOPs



Lead- Mid dose



Tributyltin- Mid dose





Conclusions



- To date, there are few AOPs focused on DNT Adverse Outcomes
 - Especially if thyroid-related AOPs are considered (excluded)
- The Omics approaches identify common diseases, molecular functions, upstream regulators and canonical pathways associated with positive responses in the DNT NAMs
 - Data for more chemicals are needed to confirm this
 - If common regulators and pathways are identified, this might result in novel DNT NAMs
- Omics approaches also identify unique responses to each chemical at multiple levels of organization.
- Using Omics approaches and NAMs data, putative AOPs can be identified
 - These putative AOPs need development, but provide a link between DNT NAMs data, key events and adverse outcomes related to human disease



Thank you!
Questions?




EPA ORD Colleagues:


- Kathleen Wallace
- Theresa Freudenrich
- Brian Chorley
- David Gallegos
- Carmen Marable
- Chris Frank
- Matthew Henderson
- Susan Hester
- Roland Seim




Domoic Acid




Haloperidol




DNA Synthesis Inhibitors



Cypermethrin



Deltamethrin




Functional alterations in the MEA NFA


- Fungicides
- GABA-A Receptor
- Metals
- Parent/metabolite




Tebuconazole




Flusilazole




Cadmium




Triethyltin bromide




Tributyltin Oxide




Lead Acetate




Heptachlor Epoxide




Lindane




Bis(2-ethylhexyl) phthalate




Sodium Arsenite




PBDE-47




Methylchloroisothiazolinone




Dieldrin




Fipronil




Chlorpyrifos Oxon



Chlorpyrifos



Permethrin



Paraquat

